# Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

> **NCT05116800** · PHASE2 · WITHDRAWN · sponsor: **Brown University**

## Conditions studied

- Soft Tissue Sarcoma
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
- Leiomyosarcoma
- Liposarcoma
- Angiosarcoma
- Synovial Sarcoma
- Rhabdomyosarcoma
- Spindle Cell Sarcoma
- High Grade Sarcoma
- Bone Sarcoma
- Osteosarcoma
- Ewing Sarcoma of Bone

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** 9-ING-41
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05116800
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2030-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND withdrawn
- **Last updated:** 2021-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116800, "Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05116800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*